Abstract
Introduction

Pulmonary lymphangitic carcinomatosis (PLC) is a serious situation and provides severe dyspnea and intractable cough. In addition, prognoses of patients with cancer of unknown primary site (CUP), who have multiple metastatic organs, have been very poor (1, 2). Although improved outcomes utilizing cisplatin-containing chemotherapy for some CUPs have been achieved, most CUPs remain relatively unresponsive to systemic chemotherapy. We present herein a case of CUP with metastases in several organs and PLC, which improved dramatically with TS-1 containing chemotherapy.
Case Report
A 37-year-old man was referred to our hospital with complaints of dyspnea and general fatigue. Chest 
F i g u r e 2 . Ch e s t CT s c a n o n a d mi s s i o n r e v e a l e d mu l t i p l e n o d u l e s o f u p t o 5 mm i n d i a me t e r a n d t h i c k e n e d b r o n c h o v a s c u l a r b u n d l e s i n b o t h l u n g s .
F i g u r e 3 . T h e s p e c i me n o b t a i n e d b y c e r v i c a l l y mp h n o d e d i s s e c t i o n wa s d i a g n o s e d p a t h o l o g i c a l l y a s p o o r l y d i f f e r e n t i a t e d c a r c i n o ma , wh i c h d i d n o t i n d i c a t e t h e p r i ma r y s i t e .
4). A previous report indicated that these symptoms usually preceed the emergence of radiographic abnormalities (5). The radiographic characteristic of PLC is a diffuse reticular network which radiates from the hilum to the lung field (3, 4). The reticular network reflects a thickening of the interlobular septa secondary to dilation of lymphatics by cancer cell invasion. In addition, the characteristics of PLC on the radiograph are septal Kerley's lines, hilar lymphadenopathy and pleural effusion. In the present patient, the findings on chest CT scan led to the diagnosis of PLC based on the progression of dyspnea and the thickness of the bronchovascular bundles in both lungs.
There c k n e s s o f b r o n c h o v a s c u l a r b u n d l e s l e s s e n e d a n d mo s t o f  t h e p u l mo n a r y n o d u l e s h a d d i s a p p e a r e d o n c h e s t CT s c a (11, 12) . Several platinum-based regimens have produced higher response rates than those reported with previous regimens (13, 14) .
F i g u r e 4 . Ch e s t r a d i o g r a p h a f t e r t h e f o u r t h c y c l e o f t h e c h e mo t h e r a p y s h o we d d i s a p p e a r a n c e o f r e t i c u l o n o d u l a r s h a d o w a n d p u l mo n a r y n o d u l e s .
F i g u r e 5 . Af t e r t h e f o u r t h c y c l e o f t h e c h e mo t h e r a p y , t h e t h i
TS-1, a combination of ftorafur and two modulators, gimestat (CDHP) and oxonic acid, has been widely used in
Japan for the treatment of advanced gastrointestinal and lung cancers; much attention has been paid to attempts to increase its antitumor effect by combining it with cisplatin (15) (16) (17) 
